---
document_datetime: 2025-01-17 15:31:02
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/balversa-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: balversa-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.2361435
conversion_datetime: 2025-12-19 10:21:51.056684
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Balversa

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                      |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0001              | Update of section 4.8 of the SmPC in order to add cataract as a new ADR with frequency common based on a review of new information observed in clinical studies and in the post marketing setting. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of | 28/11/2024                          |                                             | SmPC and PL                      | Update of section 4.8 of the SmPC in order to add cataract as a new ADR with frequency common. For more information, please refer to the Summary of Product Characteristics. |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| the most common ADRs in the SmPC section 4.8 and to make editorial corrections in the SmPC and Package Leaflet. The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet.   | C.I.4 - Change(s) new quality, preclinical, data   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|